LAB21 Limited Secures European and USA Patents for HCV Drug Resistance Genotyping  
5/15/2012 10:56:14 AM

CAMBRIDGE, England--(BUSINESS WIRE)--Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.